Zoetis Inc (ZTS)

49.99
0.17 0.34
NYSE : Health Care
Prev Close 49.82
Open 49.68
Day Low/High 49.55 / 49.96
52 Wk Low/High 38.26 / 53.14
Volume 1.03M
Avg Volume 3.71M
Exchange NYSE
Shares Outstanding 493.83M
Market Cap 24.25B
EPS 0.70
P/E Ratio 35.32
Div & Yield 0.38 (0.80%)

Latest News

Valeant Shares Are Destroyed After Disastrous Third Quarter

Valeant Shares Are Destroyed After Disastrous Third Quarter

The troubled drugmaker's new CFO hinted that 2017 top- and bottom-line figures would be lower than 2016 levels.

Uncertain Times; Themes That Endure: Jim Cramer's Best Blogs

Uncertain Times; Themes That Endure: Jim Cramer's Best Blogs

Jim Cramer ponders the preciousness of credibility.

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer says the market can have many winners.

Trending Tickers: ZTS, AGN, WFT, MRO

Trending Tickers: ZTS, AGN, WFT, MRO

Zoetis shares were climbing off an earnings beat and raised 2016 guidance.

Jim Cramer: Zoetis Is a Well Run Company

Jim Cramer: Zoetis Is a Well Run Company

Jim Cramer says Zoetis, an animal health company, is well run.

Cramer: These Themes Stand the Test of Turbulent Times

Cramer: These Themes Stand the Test of Turbulent Times

Teeth, pets, video games, eating at home are evidence of strong theses.

Zoetis (ZTS) Stock Higher on Q3 Beat, Raised Guidance

Zoetis (ZTS) Stock Higher on Q3 Beat, Raised Guidance

Zoetis (ZTS) reported 2016 third quarter results that topped analysts' expectations and upped its outlook on Wednesday.

Zoetis Reports Third Quarter 2016 Results

Zoetis Reports Third Quarter 2016 Results

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2016 and updated its guidance for full year 2016 and 2017.

What to Look for When Zoetis (ZTS) Posts Q3 Earnings

What to Look for When Zoetis (ZTS) Posts Q3 Earnings

Zoetis (ZTS) is set to report its 2016 third quarter results before Wednesday's market open.

Jim Cramer -- Buy Zoetis, Idexx Over Freshpet

Jim Cramer -- Buy Zoetis, Idexx Over Freshpet

Jim Cramer says Freshpet is only a takeover play and suggests buying Zoetis or Idexx Labs instead.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Here's a window into what institutional investors may be doing and how to profit from that.

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

The animal health industry looks poised for growth, analysts say, and Idexx Laboratories IDXX stands to benefit.

Zoetis To Participate In The 25th Annual Credit Suisse Healthcare Conference

Zoetis To Participate In The 25th Annual Credit Suisse Healthcare Conference

Zoetis Inc. (NYSE:ZTS) will participate in the 25th Annual Credit Suisse Healthcare Conference on Tuesday, Nov.

Zoetis Declares Fourth Quarter 2016 Dividend

Zoetis Declares Fourth Quarter 2016 Dividend

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2016 dividend payable to holders of the company's common stock of $0.

Zoetis To Host Webcast And Conference Call On Third Quarter 2016 Financial Results

Zoetis To Host Webcast And Conference Call On Third Quarter 2016 Financial Results

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.

Evelyn Ortiz, Chief Talent Officer At Zoetis, Is The Company's 2016 Working Mother Of The Year. She Is Pictured Here With Her Husband, Victor And Daughter, Rosie. (Photo: Zoetis)

Evelyn Ortiz, Chief Talent Officer At Zoetis, Is The Company's 2016 Working Mother Of The Year. She Is Pictured Here With Her Husband, Victor And Daughter, Rosie. (Photo: Zoetis)

Zoetis Inc. (NYSE:ZTS) today announced that it has been named one of Working Mother Magazine's "100 Best Companies for Working Mothers" for the third consecutive year.

Valeant's $1.5 Billion 'Capital Hole' -- and $31 Billion in Debt

Valeant's $1.5 Billion 'Capital Hole' -- and $31 Billion in Debt

It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.

Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'

Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'

It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.

Pet Pharma Is the Newest Growth Sector

Pet Pharma Is the Newest Growth Sector

Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.

Nervous Pooch? There's a Drug for That

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.

Zoetis Remains Attractive Alternative Healthcare Investment

Zoetis Remains Attractive Alternative Healthcare Investment

Zoetis' valuation doesn't reflect opportunities from innovation, operational improvements, and capital allocation, according to one analyst.

Zoetis (ZTS) Stock is a New 'Buy', Aureus Asset Management CEO Firestone Tells CNBC

Zoetis (ZTS) Stock is a New 'Buy', Aureus Asset Management CEO Firestone Tells CNBC

Zoetis (ZTS) stock is a smart buy for investors as a result of its growing pet business, Aureus Asset Management CEO Karen Firestone said on CNBC.

'Mad Money' Lightning Round: Lockheed Martin Can Fly to $210

'Mad Money' Lightning Round: Lockheed Martin Can Fly to $210

Cramer says McCormick is up too much and he's not chasing Clayton Williams Energy.

Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street

Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street

There are too many companies in just about every sector of this market, Cramer says.

Valeant's C-Suite Sees Another Shake-Up

Valeant's C-Suite Sees Another Shake-Up

Paul Herendeen, former CFO of Zoetis, will assume those duties as his new employer eyes divestitures.

Zoetis (ZTS) Stock Down, Appoints New CFO

Zoetis (ZTS) Stock Down, Appoints New CFO

Zoetis (ZTS) announced that Glenn David would be its new CFO effective immediately.

Valeant Shares Rise on New CFO Appointment

Valeant Shares Rise on New CFO Appointment

Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.

Jim Cramer: New Valeant CFO is 'Solid'

Jim Cramer: New Valeant CFO is 'Solid'

Valeant's new CFO Paul Herendeen is a 'solid' performer and a welcome addition to the beleaguered company, says Jim Cramer